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Objectives: To investigate whether daily systemic and/or topical medication contributes to the development of oral 
lichen planus (OLP) lesions.
Study Design: The study involved 110 OLP patients and 76 control subjects, matched by age, race and sex. The 
analyzed data included medical records, drug intake and topical medication. Criteria for analysis of drug intake 
included: (1) ATC-code drug classification; (2) number of different drugs used daily in the categories of monop-
harmacy (1 drug), minor polypharmacy (2–4 drugs), and major polypharmacy (> 5 drugs); and (3) drugs impli-
cated in lichenoid reactions (DILRs).
Results:  Sixty (54.5%) of the 110 OLP patients reported daily medication (prior to the appearance of the OLP 
lesion) compared to 52 (68.4%) of the 76 control subjects. No statistical difference was found between the two 
groups in terms of systemic diseases, number of medicated individuals in the categories of mono- and polyphar-
macy, nor use of DILRs (P > 0.05). Regarding the clinical forms and site of involvement, a statistically significant 
difference was only found for the clinical erosive form of OLP, seen more frequently in non-DILR (P = 0.04) and 
nonmedicated OLP patients (P = 0.02) than in DILR OLP patients. Daily use of topical oral medication was re-
ported by 2 (1.8%) OLP patients and 1 (1.3%) control subject.
Conclusions:  It seems that the use of systemic medication does not lead to a significant increase in the incidence of 
OLP lesions. For their part, lichenoid drug reactions are likely to occur only in a very low percentage of patients.
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Introduction
Lichen planus (LP) is an inflammatory mucocutaneous 
disease of unknown etiology, and thought to arise as a 
result of an immune response –mainly by CD8+ lym-
phocytes– to antigens on lesional keratinocytes (1,2). 
Oral lichen planus (OLP) affects from 0.1 to about 4% 
of individuals, occurring mostly in middle-aged adults, 
with a female predominance at a ratio of approximately 
2:1 (3,4).  
Several studies have suggested a possible relationship 
between OLP and daily intake of medicine (3, 5-7). OLP 
lesions presumed to be related to long-term drug intake 
are referred to as lichenoid drug reactions (LDR). The 
diagnosis of LDR usually relies on subjective criteria 
since the clinical and histopathological features of LDR 
lesions are identical or similar to those of idiopathic 
OLP lesions. Additionally, it is very difficult to iden-
tify the drug associated to LDR based on the patient’s 
medical history. The best criterion for diagnosing LDR 
is based on the observation that the lesion remits with 
drug withdrawal and returns on re-challenge, but this is 
almost always impractical because of the need for pa-
tient safety (6–9).
Many types of drugs have been implicated as a causa-
tive factor for LDR, especially the non-steroidal anti-
inflammatory drugs. In one study involving 75 patients 
with OLP, of whom 20 were taking nonsteroidal anti-
inflammatory drug, 7 had a complete resolution of their 
oral lesions after withdrawal of the drug. Of these 7 pa-
tients, 2 produced a recurrence when later rechallenged 
with the offending drug (9). 
There have been few articles comparing the profile of 
drug intake by OLP patients with that of a control group 
(4,10). The purpose of the present study was to investi-
gate whether the daily systemic and/or topical medicine 
used by patients with OLP contributes to the develop-
ment of their oral lesions. A control group matched by 
age, race and sex without oral lesions was included for 
comparison of medication intake.
Material and Methods
The study group comprised 110 patients (87 female, 
79.1%; 23 male, 20.9%, ratio f/m = 3.8:1) with OLP re-
ferred to the clinic of Oral Diagnosis, School of Den-
tistry at the University of São Paulo, during the period 
from May 2005 to July 2009. The mean age of patients 
with LPO was 53.6 years (range 27-95 years); 80 were 
white (72.7%) and 30 nonwhite (27.2%). The control 
group was composed of 76 patients (59 female, 77.6%; 
17 male, 22.4%) without oral and/or cutaneous lichen 
planus or autoimmune diseases. The selection of the 
control group was made among individuals who came 
to our clinic seeking dental treatment. The mean age of 
this group was 53.7 years (range 26–82 years); 50 were 
white (65.8%) and 26 nonwhite (34.2%). OLP patients 
suspected as having extra-oral lesions of LP were re-
ferred to a Dermatologic unit at the School of Medicine, 
University of São Paulo, for further evaluation. This 
study was approved by the Committee on Ethics of the 
University of São Paulo.
Patients with OLP were evaluated in the initial consul-
tation through application of a clinical protocol. The 
diagnosis of OLP was made according to the criteria 
described by Kramer et al. (11), i.e., clinically, by the 
presence of white papules and/or striae usually with 
bilateral involvement, and histopatholgically, by signs 
of “liquefaction degeneration” in the  basal cell layer 
(degenerative changes to the basal cells) along with 
the presence a well-defined band-like zone of inflam-
matory infiltrate confined to the superficial part of the 
connective tissue, this infiltrate being composed almost 
exclusively by lymphocytes, and absence of epithelial 
dysplasia. Patients suspected as having oral lichenoid 
contact reaction to amalgam fillings were not included. 
Clinical characteristics of the OLP lesions were ana-
lyzed, including the clinical forms, site, duration, and 
presence of symptomatology. The clinical forms were 
categorized into reticular, atrophic, erosive and plaque. 
The reticular form was characterized by the presence of 
white striae and/or papules exhibiting a lace-like and/
or irradiated pattern; the atrophic form by an erythema-
tous lesion associated with reticular features; the erosive 
form by a combination of ulceration and features of the 
atrophic form; and the plaque-like by a raised, flat white 
lesion with a smooth or rough surface with the presence 
of reticular features either at the periphery of the plaque 
or elsewhere in the oral mucosa. Prior to biopsy all OLP 
patients were tested for the presence of Candida spp. by 
PAS (periodic acid-Schiff), and only those patients who 
tested positive were treated with antifungal agent (topi-
cal Nystatin oral suspension, used as mouthwash) for 2 
weeks before biopsy.  
Data collected for analysis of both groups included age, 
sex, race, medical records, systemic disease, drug in-
take and topical medication such as mouthwashes. Cri-
teria for analysis of drug intake in both groups included: 
(1) drug classification according to the ATC code (12); 
(2) the number of different drugs used daily in the cat-
egories of monopharmacy (1 drug), minor polypharma-
cy (2–4 drugs), and major polypharmacy (> 5 drugs); 
and (3) drugs reported to have the potential to induce 
oral and/or cutaneous LDR, according to Scully and 
Bagan (8). Data were analyzed by unconditional logis-
tic regression. Associations between lichen planus and 
covariates were assessed by odds ratio (OR) point with 
a 95% confidence interval. Fisher’s exact test was used 
when the observed frequencies were less than 5. The 
statistical significance level was set for P ≤ 0.05.  
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Results
Of the 110 OLP patients, 60 (54.5%) had been using daily 
medication since prior to the appearance of the OLP le-
sion (termed as medicated OLP patients), 22 (20%) were 
presently using daily medication, but had began using 
it only after the appearance of the OLP lesion, while 28 
(25.5%) did not report daily use of medication. These 2 
latter categories of patients were considered as nonmedi-
cated OLP patients, since in both cases there was no pos-
sibility for drugs to have played a part in the onset of their 
OLP lesions. For the control group, daily use of medica-
tion was reported by 52 (68.4%) of the 76 subjects.  The 
clinical profiles of the OLP group and control group are 
shown in (Table 1), there being no significant statistical 
difference between the two groups in terms of sex, race, 
systemic diseases or consumption of tobacco or alcohol 
(P > 0.05). Extra-oral lesions of LP were found in 11 OLP 
patients (10%). Of these, 1 had cutaneous and genital 
lesions, 8 had only cutaneous lesions, while 2 had only 
genital lesions. The dermatologic diagnosis of the extra-
oral lesions was made on a clinical basis supported by the 
oral and histopathologic data of the OLP lesions, with no 
additional biopsy being taken. The PAS-test for Candida 
was positive in 19 cases (17.3%). In these patients, most 
of the lesions were of reticular or atrophic form, 3 cases 
were of erosive form. Thirteen were symptomatic while 
6 were symptomless. After antifungal treatment patients 
reported subjective improvement of their symptoms, but 
the clinically observed appearance of their lesions re-
mained unchanged.
Patients
LPO Group (n = 110) Control Group (n = 76)  
Male (%) Female (%) Total (%) Male (%) Female (%) Total (%) 
  Number 23 (20.9) 87 (79.1) 110 (100) 17 (22.4) 59 (77.6) 76 (100) 
 Mean age (range) yr 52.2 (36–72) 54 (27–95) 53.6 (27–95) 57.7 (44–76) 52.4 (26–82) 53.7 (26–82) 
Race       
White 15 (65.2) 65 (74.7) 80 (72.7) 11 (61.1) 39 (67.2) 50 (65.8) 
Non-white 8 (34.8) 22 (25.3)  30 (27.3) 6 (33.3) 20 (34.5) 26 (34.2) 
History of disease       
 Hypertension 6 (26.1) 26 (29.9) 32 (29.1) 6 (33.3) 20 (34.5) 26 (34.2) 
 Diabetes 6 (26.1) 12 (13.8) 18 (16.4) 3 (16.7) 6 (10.3) 9 (11.8) 
 Hypotireoidism – 12 (13.8) 12 (10.9) – 4 (6.9) 4 (5.3) 
 Hepatitis  B 2 (8.7) 3 (3.5) 5 (4.5) – 2 (3.4) 2 (2.6) 
 Hepatitis  C – 2 (2.3) 2 (1.8) – 2 (3.4) 2 (2.6) 
 Anemia history 1 (4.3) 13 (14.9) 14 (12.7) 2 (11.1) 7 (12.1) 9 (11.8) 
 Allergy 1 (4.3) 17 (19.5) 18 (16.4) 1 (5.9) 10 (17.2) 11 (14.5) 
Habits       
 Present smokers 1 (4.3) 10 (11.5) 11 (10) 2 (11.1) 12 (20.7) 14 (18.4) 
Ex-smokers (> 2 years) 14 (60.9) 23 (26.4) 37 (33.6) 8 (44.4) 12 (20.7) 20 (26.3) 
 Present drinker 11 (47.8) 13 (14.9) 24 (21.8) 10 (55.6) 14 (24.1) 25 (32.9) 
Ex-drinker (> 2 years) 5 (21.8) 3 (3.5) 8 (7.3) 2 (11.1) 2 (3.4) 4 (5.3) 
Table 1. Clinical profile of the OLP patients and control subjects.
n = number of patients.
Med Oral Patol Oral Cir Bucal. 2011 Sep 1;16 (6):e750-6.                                                                                                                                                                              OLP and daily drug intake
e753
There was no statistically significant difference between 
the percentage of medicated OLP patients (54.5%) 
as compared with that of medicated control subjects 
(68.4%) (P = 0.08); nor was there any statistical diffe-
rence between the percentage of medicated males and 
females of the OLP group (P = 0.35) and of the control 
subjects (P = 0.93).  
The profile of drugs used among the 60 medicated OLP 
patients and the 52 medicated subjects of the control 
group is shown in (Table 2). The total number of differ-
ent drugs was 65 in the medicated OLP patients and 67 
in medicated subjects of the control group. The antihy-
pertensives were the drugs most used by the medicated 
OLP patients (41.7%) and by the medicated subjects of 
Medicated OLP patients (n = 60) N   (%) Medicated control subjects (n = 52) N   (%) 
Antihypertensives 25 (41.7) Antihypertensives† 29 (55.8) 
C02A Antiadrenergic agents, centrally 
acting 1 (1.9) 
C03A Low-ceiling diuretics, thiazides 8 (13.3) C03A Low-ceiling diuretics, thiazides 11 (21.1) 
C03B Low-ceiling diuretics, excluding 
thiazides 4 (6.7) 
C03B Low-ceiling diuretics, excluding 
thiazides 2 (3.8) 
 C03C High-ceiling diuretics 1 (1.9) 
C03D Potassium-sparing agents 1 (1.7)   
C03E Diuretics and potassium-sparing 
agents in combination 1 (1.7) 
C03E Diuretics and potassium-sparing 
agents in combination 2 (3.8) 
C07A Beta blocking agents 5 (8.3) C07A Beta blocking agents 7 (13.5) 
C07C Beta blocking agents and other 
diuretics (não-tiazídicos) 1 (1.9) 
C08C Selective calcium channel blockers 
with mainly vascular effects 2 (3.3) 
C08C Selective calcium channel blockers 
with mainly vascular effects 4 (7.7) 
C09A ACE inhibitors, plain 12 (20) C09A ACE inhibitors, plain 14 (26.9) 
C09C Angiotensin II antagonists, plain 1 (1.7) C09C Angiotensin II antagonists, plain 2 (3.8) 
C09D Angiotensin II antagonists, 
combinations 1 (1.9) 
Antidiabetics 10 (16.7) Antidiabetics 6 (11.5) 
A10B Oral blood glucose lowering drugs 9 (15) A10B Oral blood glucose lowering drugs 6 (11.5) 
A10A Insulins and analogues 1 (1.7)   
A02B Drugs for peptic ulcer and gastro-
oesophageal reflux disease (GORD) 7 (11.7) 
A02B Drugs for peptic ulcer and gastro-
oesophageal reflux disease (GORD) 6 (11.5) 
A12A Calcium 5 (8.3) A12A Calcium 3 (5.8) 
B01A Antithrombotic agents 9 (15) B01A Antithrombotic agents 5 (9.6) 
C10ALipid modifying agents, plain 5 (8.3) C10ALipid modifying agents, plain 3 (5.8) 
H03A Thyroid preparations 9 (15) H03A Thyroid preparations 3 (5.8) 
M01A Anti-inflammatory and 
antirheumatic products, non-steroids 7 (11.7) 
M01A Anti-inflammatory and 
antirheumatic products, non-steroids 5 (9.6) 
N05B Anxiolytics 10 (16.7) N05B Anxiolytics 4 (7.7) 
N06A Antidepressants 8 (13.3) N06A Antidepressants 9 (17.3) 
Table 2.  Drugs most used by OLP patients and control subjects.
n = number of patients
†P = 0.02; OR = 0.48 (95% CI: 0.25–0.91).
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the control group (55.8%), with the angiotensin-con-
verting enzyme inhibitors being the most common an-
tihypertensive drugs in both groups, used by 20% of 
the medicated OLP patients and 26.9% of the medicated 
control subjects. The anxiolytics (16.7%), antidiabetics 
(16.7%), thyroid preparations (15%), antithrombotic 
agents (15%), antidepressants (13.3%), drugs for peptic
ulcer and gastro-oesophageal reflux disease (11.7%) and 
non-steroidal anti-inflammatories (11.7%) comprised 
the other drugs most consumed by the medicated OLP 
patients, which, for the medicated subjects in the control 
group, were the antidepressants (17.3%), antidiabetics 
(11.5%), drugs for peptic ulcer and gastro-oesophageal 
reflux disease (11.5%) antithrombotic agents (9.6%), 
non-steroidal anti-inflammatories (9.6%) and anxiolyt-
ics (7.7%). In terms of the categories of drugs taken, the 
only statistically significant difference was that a higher 
percentage of control subjects were taking antihyper-
tensives as compared to the OLP patients, P = 0.02; OR 
= 0.48 (95% CI: 0.25–0.91). 
There was no statistically significant difference when 
the medicated OLP patients and medicated control sub-
jects were compared in terms of monopharmacy, minor 
and major polypharmacy (P > 0.05; (Table 3A). Daily 
use of topical oral medication was reported by only 2 
(1.8%) of the 110 OLP patients and by 1 (1.3%) 76 of the 
control group.
Thirty-nine (65%) of the 60 medicated OLP patients and 
37 (71.1%) of the 52 medicated subjects in the control 
group were using drugs implicated in lichenoid reac-
tions (DILRs), there being no statistically significant 
difference between these two groups in terms of using 
DILRs, regardless of the number of medications used 
daily (P > 0.05; (Table 3B).      
The percentage of the clinical forms of OLP lesions in 
the patients using DILRs compared with the non-DILR 
and nonmedicated OLP patients are shown in (Table 4). 
The reticular and atrophic OLP lesions were the most 
prevalent forms in the two groups, with no statistically 
significant difference between them (P > 0.05). The 
erosive form was seen less frequently in the patients using 
DILRs than in the non-DILR and nonmedicated pa-
tients, this difference being statistically significant (P < 
0.05). The plaque form was only observed in 3 patients 
Table 3. A) Classification of medicated OLP patients and medicated subjects of the control group according to the number of different 
drugs taken daily. B) Medicated OLP patients and medicated control subjects using drugs implicated in lichenoid reactions (DILRs). C) 
Nonmedicated OLP patients and control subjects. 
n = number of patients 
DILRs = drugs implicated in lichenoid reaction, based on Scully and Bagan (8)
* P = 0.09
** P = 0.24
*** P = 0.13
† P = 0.09
†† P = 0.26
 OLP Group (n = 110)  Control Group (n = 76) 
Male (%) 
N = 23 
Female (%) 
n = 87 
Total (%) 
n = 110 
Male (%) 
N = 18 
Female (%)  
N =  58 
Total (%) 
n = 76 
A) Medicated subjects  
using any medication  
*Monopharmacy (%) 10 (43.5) 15 (17.2) 25 (22.7)  4 (22.2) 19 (32.8) 23 (30.3) 
**Minor polypharmacy (%) 2 (8.7) 26 (29.9) 28 (32.2)  4 (22.2) 17 (29.3) 21 (27.6) 
***Major polypharmacy (%) 3 (13) 4 (4.6) 7 (6.4)  3 (16.7) 5 (8.6) 8 (10.5) 
                Total 15 (65.2) 45 (51.7) 60 (54.5)  11 (61.1) 41 (70.7) 52 (68.4) 
B)  Medicated subjects  
using DILRs 
       
† Monopharmacy (%) 4 (17.3) 15 (17.2) 19 (17.2)  9 (50) 11 (19) 20 (26.3) 
††Minor polypharmacy (%) 2 (8.6) 18 (20.6) 20 (18.2)  – 17 (29.3) 17 (22.3) 
Major polypharmacy (%) – – –  – – – 
                    Total 6 (26.0) 33 (37.9) 39 (35.4)  9 (50) 28 (48.3) 37 (48.6) 
C) Nonmedicated subjects 8 (34.8) 42 (48.3) 50 (45.5)   7 (38.9) 17 (29.3) 24 (31.6) 
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using DILRs and in 3 of the non-DILR/nonmedicated 
patients.    
The buccal mucosa, tongue and gingiva were the sites 
most affected in patients using DILRs (100, 46.1, and 
48.7%, respectively) and in non-DILR/nonmedicated 
patients (91.6, 46.5, and 43.7%, respectively). The symp-
toms of oral discomfort, burning or pain were reported 
by 66.7% of those using DILR and in 67.6% of the non-
DILR and nonmedicated patients, with no statistically 
significant difference between these two groups (P > 
0.05). 
Distribution of the lesions showed a predominant bi-
lateral involvement of the lesions, occurring in 94.9% 
of OLP patients using DILRs and in 97.2% of the non-
DILR/nonmedicated patients, with no significant sta-
tistical difference between these two groups (P > 0.05; 
(Table 4). 
Discussion
The clinical profile of the OLP patients in this study 
shares many similarities with those reported by other 
authors, in terms of female predominance (female/male 
ratio 3.8:1), age of diagnosis (predominantly over 50 
years) and the clinical pattern of the lesions (predomi-
nance of the reticular form with bilateral distribution) 
(4, 13–15). 
The female predominance reported in the present study 
was even higher than those found in other studies (4,10, 
14–16), in which the female/male ratio varied from 1.5:1 
to 2.1:1. One possible explanation for this difference is 
that, routinely, more women (64.5%) than men (35.5%) 
come to our clinic for a diagnosis of some type oral mu-
Patients using DILR 
(n = 39)
Patients using non-DILR
 (n = 21)
Nonmedicated subjects 
(n = 50)
Clinical forms of  OLP    
Reticular  (%) 36 (92.3) 18 (85.7) 46 (92.0) 
Atrophic (%) 19 (48.7) 10 (47.6) 27 (54) 
Erosive (%) 1 (2.6) 4 (19.1)† 10 (20)††
Plaque (%) 3 (7.7) 1 (4.8) 2 (4.0) 
Uni / bilateral lesions of  OLP    
Unilateral 2 (5.1) 1 (4.8)ns 1 (2.0)ns
Bilateral 37 (94.9) 20 (95.2) 49 (98) 
n = number of OLP patients
† Fisher’s exact test, 2 tailed, P = 0.04; OR = 0.11; 95% CI (0.01–1.21)
††Fisher’s exact test, 2 tailed, P = 0.02; OR = 0.11; 95% CI (0.01–0.87)
ns = Nonsignificant,  Fisher’s exact test, 2 tailed, P  = 1.0
Table 4. Comparison of the frequency of the clinical forms and distribution (uni/bilateral) of lesions in OLP patients using DILR with 
those of patients using non-DILR and no drugs. 
cosa lesion. In only 2 studies (5,13), were the reported 
female/male ratio in OLP lesions (2.8: 1 and 3:1, respec-
tively) fairly close to that observed in the present study.
Although many drugs have been reported as potential 
inducers of LDRs (5,8), the non-steroidal anti-inflam-
matory drugs (NSAIDs) and the antihypertensives, 
mostly the angiotensin-converting enzyme inhibitors 
(ACE inhibitors), are the drugs most frequently impli-
cated in LDRs (3,9,17). Two studies have shown a com-
plete identification of NSAIDs as LDR inducers, with 
case history strongly suggesting a relationship between 
NSAID intake and the onset of OLP, with complete 
resolution or marked improvement of the lesions when 
these drugs were withdrawn as well as recurrence when 
patients were again given the offending drug (9,10). 
In the present study, the medicated OLP patients and 
medicated control-group subjects exhibited a similar 
profile in terms of daily medicine intake. However, this 
and another similar study (10) have shown that more 
control subjects were taking antihypertensives than 
OLP patients, with a statistically significant difference. 
These findings indicate that the antihypertensives do 
not likely act as LDR inducers, in fact it could be ar-
gued, pending further studies, that they are associated 
with a lower risk of OLP. A further controlled study (4), 
found no statistical difference between the percentage 
of subjects taking antihypertensives in the OLP and 
control groups. To date, the present study, along with 
(4) and (10) constitute the only 3 controlled studies in 
this regard. 
In terms of the types of OLP lesions, the erosive form 
was found at a statistically significance greater frequen-
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cy in non-DILR and nonmedicated OLP patients than in 
patients taking DIRLs. This finding does not agree with 
a general tendency in the literature to associate the ero-
sive form with DILR intake, but it is in agreement with 
the results of a large study involving 808 OLP patients 
(15), where the authors did not find a predominance of 
the erosive form in patients taking ACE inhibitors. 
So, while there is no disagreement among authors 
that some drugs can cause LDR lesions, in light of the 
present study and others (15,16), it seems that the preva-
lence of LDR lesions is low.    
It is also generally agreed that OLP affects predomi-
nantly women, possibly suggesting a genetic predispo-
sition to the development of OLP.  This has given rise to 
the hypothesis that drug intake is correlated, in women, 
with an enhanced susceptibility to developing OLP le-
sions.  However, only in one study have drug histories 
been found to be significantly more prevalent in female 
patients with OLP as compared to males (4). Other stud-
ies, in agreement with the present study, have found that 
the medical status of female patients with OLP did not 
differ significantly from that of males (10,18). 
OLP is considered a cell-mediated immunological di-
sease, but what elicits the immune response is uknown. 
Likewise, the role of drugs in the etiology of LDRs is 
poorly understood and most likely complex.  It seems 
clear, however, that a majority of OLP cases are not di-
rectly linked to the use of systemic medication, which 
is in accordance with the findings of a previous study 
(16).   Diagnosis of LDR lesions can only be made by 
verifying that remission occurs upon withdrawal of 
medication coupled with recurrence on re-challenge. In 
cases of LDRs where the regime of medication cannot 
be substituted, reduced or withdrawn, symptomatic pa-
tients can be treated with topical medication, mostly by 
application of corticosteroids (19,20). 
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